BRAF and melanoma: The screening procedure identified a BRAF inhibitor active in melanoma Malme-3M cells (Figure 1B) (IC50 = 0.85 ± 0.19 μM) but virtually ineffective in thyroid 8505C and KTC-1 cancer cells (IC50 > 10 μM, not shown).